Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC raised its stake in Ikena Oncology, Inc. (NASDAQ:IKNA) by 88.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,222 shares of the company’s stock after purchasing an additional 9,495 shares during the quarter. SG Americas Securities LLC’s holdings in Ikena Oncology were worth $40,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of IKNA. JPMorgan Chase & Co. grew its position in Ikena Oncology by 25.4% in the 1st quarter. JPMorgan Chase & Co. now owns 17,172 shares of the company’s stock valued at $104,000 after buying an additional 3,482 shares during the last quarter. BlackRock Inc. raised its holdings in Ikena Oncology by 9.5% during the first quarter. BlackRock Inc. now owns 1,493,161 shares of the company’s stock worth $9,108,000 after purchasing an additional 129,284 shares in the last quarter. Vanguard Group Inc. lifted its position in Ikena Oncology by 1.0% in the first quarter. Vanguard Group Inc. now owns 789,999 shares of the company’s stock valued at $4,819,000 after purchasing an additional 7,605 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Ikena Oncology by 5.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 66,810 shares of the company’s stock valued at $408,000 after purchasing an additional 3,276 shares in the last quarter. Finally, State Street Corp boosted its holdings in Ikena Oncology by 18.8% in the 1st quarter. State Street Corp now owns 404,602 shares of the company’s stock valued at $2,468,000 after purchasing an additional 63,988 shares in the last quarter. Institutional investors and hedge funds own 75.00% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Wedbush reissued an “outperform” rating and set a $8.00 target price on shares of Ikena Oncology in a research note on Tuesday, March 12th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Ikena Oncology in a report on Tuesday, March 19th.

Ikena Oncology Trading Up 5.6 %

IKNA stock opened at $1.33 on Monday. Ikena Oncology, Inc. has a 52 week low of $1.02 and a 52 week high of $7.64. The company has a market cap of $64.19 million, a P/E ratio of -0.81 and a beta of 0.33. The company’s 50-day moving average price is $1.41 and its 200 day moving average price is $1.99.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings results on Tuesday, March 12th. The company reported ($0.41) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.41). The firm had revenue of $0.66 million during the quarter, compared to analyst estimates of $2.39 million. On average, equities research analysts expect that Ikena Oncology, Inc. will post -1.5 earnings per share for the current year.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.